We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing

By LabMedica International staff writers
Posted on 19 Apr 2024
Print article
STI Scout runs on the ultra-portable Scout Hub device (Photo courtesy of Scout)
STI Scout runs on the ultra-portable Scout Hub device (Photo courtesy of Scout)

Gonorrhea ranks as the second most commonly reported bacterial sexually transmitted infection (STI), with around 82 million global cases in 2020. The infection can lead to severe health consequences like pelvic inflammatory disease, chronic pelvic pain, and infertility. Many patients may not show symptoms, leading to underreported cases and highlighting the need for more accessible, accurate, and cost-effective diagnostic solutions. Now, a new point-of-care test aims to expand access to STI testing by providing affordable, accurate, and convenient diagnosis.

Scout (Santa Clara, CA, USA) is developing the STI Scout test to identify and distinguish between Neisseria gonorrhoeae (Ng) and Chlamydia trachomatis (Ct). This new test delivers results in just 30 minutes at a cost expected to be less than half that of current testing methods. STI Scout can use either first void urine samples or vaginal swabs. The test runs on the Scout Hub device and is integrated with the Scout Connect mobile app, which guides users through the testing process, records results, and will eventually link patients to healthcare providers. Future developments aim to include features that could recommend specific treatments for gonorrhea based on antibiotic resistance.

Scout's innovative test is powered by their patented Loop-de-Loop chemistry, an isothermal technology previously validated for highly accurate SARS-CoV-2 detection. This technology is part of Scout's system currently holding FDA Emergency Use Authorization for point-of-care application, with additional over-the-counter (OTC) use pending. CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has awarded Scout USD 1 million to demonstrate proof-of-concept and feasibility ahead of developing STI Scout. This funding will support the expansion of Scout's testing menu to offer at-home STI testing, as well as facilitate deployment in point-of-care settings like STI clinics and urgent care centers.

"Our goal is to improve access to accurate diagnostics for everyone. Scout's approach benefits clinicians and patients by providing timely, accurate results which can lead to earlier diagnosis and treatment of patients. Importantly, Scout also could assist healthcare providers in determining which treatments are appropriate for the patient and can assist combating the spread of antibiotic resistance bacteria" said Cam Ball, PhD, Scout CTO and Co-Founder.

"There is a need for affordable, accurate, and easy-to-use tests that expand access to testing for and proper treatment of Neisseria gonorrhoeae to urgent care centers, STI clinics, and the like", said Erin Duffy, PhD, R&D Chief of CARB-X. "Given the prevalence of gonorrhea globally, and the growing prevalence of drug-resistant gonorrhea, to diagnose quickly and affordably would allow physicians at all levels of the healthcare system to treat rapidly with the most appropriate therapy. The impact of a test like Scout's could be vast."

Related Links:

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
POCT Fluorescent Immunoassay Analyzer
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article


Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: The novel test uses an existing diagnostic procedure as its basis to target the Epstein Barr Virus (Photo courtesy of 123RF)

Blood Test Measures Immune Response to Epstein-Barr Virus in MS Patients

Multiple sclerosis (MS) is a chronic neurological condition for which there is currently no cure. It affects around three million people globally and ranks as the second most common cause of disability... Read more


view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more


view channel
Image: Insulin proteins clumping together (Photo courtesy of Jacob Kæstel-Hansen)

AI Tool Detects Tiny Protein Clumps in Microscopy Images in Real-Time

Over 55 million individuals worldwide suffer from dementia-related diseases like Alzheimer's and Parkinson's. These conditions are caused by the clumping together of the smallest building blocks in the... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.